Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knop, S
Right arrow Articles by Einsele, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knop, S
Right arrow Articles by Einsele, H
Haematologica, Vol 90, Issue 9, 1287-1288
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy

S Knop, C Straka, M Haen, R Schwedes, H Hebart, and H Einsele

We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61) weeks. Toxicity was mild and mainly hematologic.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. M. Leoni, B. Bailey, J. Reifert, H. H. Bendall, R. W. Zeller, J. Corbeil, G. Elliott, and C. C. Niemeyer
Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
Clin. Cancer Res., January 1, 2008; 14(1): 309 - 317.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.